Gatta G, Lasota M B, Verdecchia A
Department of Epidemiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Eur J Cancer. 1998 Dec;34(14 Spec No):2218-25. doi: 10.1016/s0959-8049(98)00326-8.
This study concerns the survival of European patients diagnosed between 1978 and 1989 with cancer of corpus and cervix uteri and ovary. Variations in survival in relation to age, country and period of diagnosis were examined. Data from the EUROCARE study were supplied by population-based cancer registries in 17 countries to a common protocol. Five years after diagnosis, relative survival rates were 75, 62 and 35% for cancers of the endometrium, cervix and ovary, respectively. Survival decreased markedly with age. The decrease was especially evident for ovarian cancer, which declined from 65% (15-45 years) to 18% (75+ years). In 1985-1989 there were important inter-country differences in survival for European women with gynaecological cancers: Eastern European countries were characterised by low 5-year relative survival whilst in Sweden, Austria, The Netherlands and Switzerland survival was generally higher than for other European countries. From 1978-1989, 5-year relative survival improved slightly for cervical cancer and improved more among the oldest patients. Prognosis also improved slightly for patients with ovarian tumours and this increase (around 20%) was concentrated among patients between 15 and 64 years of age. Intercountry differences in survival did not in general reduce over time, although for ovarian cancer survival differences narrowed probably in relation to the more widespread use of more effective chemotherapy. Intercountry and time differences in survival for cervical cancer are almost certainly related to variations in the effectiveness of cervical screening programmes. For corpus uteri cancer there was no improvement in survival over the period of this study and intercountry survival differences for this cancer are probably related to differences in patient management.
本研究关注1978年至1989年间被诊断患有子宫体癌、子宫颈癌和卵巢癌的欧洲患者的生存率。研究了生存率与年龄、国家和诊断时期的关系变化。欧洲癌症和治疗结果研究（EUROCARE）的数据由17个国家基于人群的癌症登记处按照共同方案提供。诊断后五年，子宫内膜癌、子宫颈癌和卵巢癌的相对生存率分别为75%、62%和35%。生存率随年龄显著下降。这种下降在卵巢癌中尤为明显，从65%（15 - 45岁）降至18%（75岁及以上）。1985 - 1989年，患有妇科癌症的欧洲女性在生存率方面存在重要的国家间差异：东欧国家的5年相对生存率较低，而在瑞典、奥地利、荷兰和瑞士，生存率总体高于其他欧洲国家。1978 - 1989年，子宫颈癌的5年相对生存率略有提高，且在年龄最大的患者中提高更为明显。卵巢肿瘤患者的预后也略有改善，这种提高（约20%）集中在15至64岁的患者中。尽管卵巢癌的生存率差异可能因更广泛使用更有效的化疗而缩小，但生存率的国家间差异总体上并未随时间减少。子宫颈癌生存率的国家间和时间差异几乎肯定与子宫颈筛查计划效果的差异有关。对于子宫体癌，在本研究期间生存率没有改善，该癌症的国家间生存率差异可能与患者管理的差异有关。
